When Fasha Mahjoor launched Neoteryx, he planned to change the way dried capillary blood is collected, to become the most significant blood microsampling innovator in the modern marketplace. In that, he and his team have surely succeeded.
Topics: Clinical Diagnostics, Clinical Trials, Alternative to Dried Blood Spot, Animal Testing, Pediatrics, RNA / DNA from Dried Blood, Capillary Blood Sampling, Vet Diagnostics, Alternative to Venipuncture, Remote Patient Monitoring, Health and Wellness, Immunosuppressants
Therapeutic drug monitoring (TDM) for immunosuppressive drugs (ISPs) is a critical component of post-tissue and organ transplantation therapy. This is because ISP drugs have high intra- and inter-subject variability and a narrow therapeutic window. Initially, quantitative analyses of ISPs such as sirolimus, cyclosporine A, tacrolimus, and everolimus used whole blood specimens.
When administering immunosuppressants, clinicians need to individualize a patient’s drug therapy. The goal is to attain an optimal balance between therapeutic efficacy and the probability of adverse effects. Patients present varying pharmacodynamics and pharmacokinetics, so achieving this goal can be challenging.
Patient-centric healthcare has taken center-stage. With the increasing access to information, patients want to play a role in treatment methods and applications. Patient-centric sampling has an important part to play.
Data collected in vivo is mandatory to make informed decisions about drug development and screening. Researchers previously relied on animal models to obtain experimental measurements. The collection of specimens was invasive, labor-intensive, time-consuming, and costly.
At Neoteryx, we work with top scientists and researchers to help facilitate and promote their revolutionary work using Mitra® microsampling devices and Volumetric Absorptive Microsampling (VAMS®) technology.